(Q39821325)

14 September 2017

In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation (English)

1 reference

14 September 2017

1 reference

1 reference

E Ranza

1

1 reference

14 September 2017

G Mazzini

series ordinal

2

1 reference

14 September 2017

A Facoetti

series ordinal

3

1 reference

14 September 2017

R Nano

series ordinal

4

1 reference

14 September 2017

24 July 2009

1 reference

Journal of Neuro-Oncology

14 September 2017

1 reference

14 September 2017

96

1 reference

14 September 2017

3

1 reference

14 September 2017

349-357

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-009-9975-4

14 September 2017

0 references

cites work

Tyrosine kinase blockers: new hope for successful cancer therapy.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-9975-4

Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-9975-4

A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571.

21 January 2018

1 reference

12 December 2020

Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.

1 reference

12 December 2020

Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK

1 reference

12 December 2020

Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation

1 reference

12 December 2020

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

1 reference

12 December 2020

Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity

1 reference

12 December 2020

Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations

1 reference

12 December 2020

Pharmacology of imatinib (STI571).

1 reference

12 December 2020

Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.

1 reference

12 December 2020

Current status of clinical trials for glioblastoma.

1 reference

12 December 2020

Characterization of an imatinib-sensitive subset of high-grade human glioma cultures

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

Protein kinase inhibitors: contributions from structure to clinical compounds

1 reference

12 December 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

12 December 2020

Malignant glioma: genetics and biology of a grave matter.

1 reference

12 December 2020

Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor

1 reference

12 December 2020

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

1 reference

12 December 2020

Identifying candidate genes involved in brain tumor formation

1 reference

12 December 2020

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

1 reference

12 December 2020

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

12 December 2020

Management of malignant gastrointestinal stromal tumours

1 reference

12 December 2020

Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth

1 reference

12 December 2020

Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

1 reference

12 December 2020

Resistance to c-KIT kinase inhibitors conferred by V654A mutation

1 reference

12 December 2020

Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines.

1 reference

12 December 2020

Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity

1 reference

12 December 2020

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

1 reference

12 December 2020

Platelet-derived growth factor in human glioma

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

The protein tyrosine kinase family of the human genome

1 reference

12 December 2020

Platelet-derived growth factor (PDGF) and glial tumorigenesis

1 reference

12 December 2020

Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops

1 reference

12 December 2020

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

12 December 2020

10.1007/S11060-009-9975-4

Identifiers

DOI

1 reference

14 September 2017

1 reference